These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3743616)

  • 1. Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
    Bührer M; Le Cotonnec JY; Wermeille M; Bircher J
    Eur J Clin Pharmacol; 1986; 30(4):407-16. PubMed ID: 3743616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group.
    J Hepatol; 1993 Feb; 17(2):227-35. PubMed ID: 8445237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis.
    Takase S; Takada A; Yasuhara M; Sato H; Matsuda Y
    Gastroenterol Jpn; 1988 Dec; 23(6):639-45. PubMed ID: 2851477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of malotilate treatment on alcoholic liver disease.
    Takase S; Matsuda Y; Yasuhara M; Takada A
    Alcohol; 1989; 6(3):219-22. PubMed ID: 2544209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of di-isopropyl 1,3 dithiol-2-ylidenemalonate (malotilate) on the hepatic changes induced by ethanol administration in the rat.
    Ryle PR; Chakraborty J; Thomson AD
    Biochem Pharmacol; 1988 Nov; 37(22):4341-51. PubMed ID: 3143367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of malotilate against galactosamine intoxication in the rat.
    Dumont JM; Maignan MF; Perrissoud D
    Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):296-310. PubMed ID: 3426350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of malotilate on alcoholic liver injury in rats.
    Matsuda Y; Takada A; Yasuhara M; Sato H
    Alcohol Clin Exp Res; 1988 Oct; 12(5):665-70. PubMed ID: 3067613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malotilate completely inhibits CCl4-induced liver cirrhosis in rats: biochemical and morphological analysis.
    Suzuki T
    Fukushima J Med Sci; 1992 Jun; 38(1):19-33. PubMed ID: 1292970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-fibrotic effect of malotilate on liver fibrosis induced by carbon tetrachloride in rats.
    Igarashi S; Hatahara T; Nagai Y; Hori H; Sakakibara K; Katoh M; Sakai A; Sugimoto T
    Jpn J Exp Med; 1986 Oct; 56(5):235-45. PubMed ID: 3027433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of malotilate on carbon tetrachloride-induced liver damage and collagen accumulation in the rat.
    Ala-Kokko L; Stenbäck F; Ryhänen L
    Biochem J; 1987 Sep; 246(2):503-9. PubMed ID: 2825640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malotilate: the new hope for a clinically effective agent for the treatment of liver disease.
    Ryle PR; Dumont JM
    Alcohol Alcohol; 1987; 22(2):121-41. PubMed ID: 3307796
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of malotilate (diisopropyl 1, 3-dithiol-2-ylidenemalonate) on chronic liver injury caused by carbon tetrachloride].
    Katoh M; Sugimoto T
    Nihon Yakurigaku Zasshi; 1982 Jul; 80(1):83-91. PubMed ID: 7173736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of isradipine in patients with chronic liver disease.
    Cotting J; Reichen J; Kutz K; Laplanche R; Nüesch E
    Eur J Clin Pharmacol; 1990; 38(6):599-603. PubMed ID: 2142648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.
    Pentikainen PJ; Neuvonen PJ; Tarpila S; Syvälahti E
    Br Med J; 1978 Sep; 2(6141):861-3. PubMed ID: 709096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of malotilate (diisopropyl 1,3-dithiol-2-ylidenemalonate) on the synthesis and movement of RNA in rat liver (author's transl)].
    Imaizumi Y; Katoh M; Sugimoto T
    Nihon Yakurigaku Zasshi; 1982 Apr; 79(4):285-91. PubMed ID: 6178659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temazepam clearance unaltered in cirrhosis.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic handling of orally administered glucose in cirrhosis.
    Kruszynska YT; Meyer-Alber A; Darakhshan F; Home PD; McIntyre N
    J Clin Invest; 1993 Mar; 91(3):1057-66. PubMed ID: 8450036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of malotilate toxicity in vitro with peripheral blood mononuclear cells as targets. A preliminary report.
    Nomura F; Ohnishi K; Ohto M
    J Hepatol; 1990 Jul; 11(1):65-9. PubMed ID: 2398268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical and pharmacokinetic characterization of a spray-dried malotilate emulsion.
    Zhang J; Gao Y; Qian S; Liu X; Zu H
    Int J Pharm; 2011 Jul; 414(1-2):186-92. PubMed ID: 21619915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of trapidil in patients with chronic liver disease.
    Berndt A; Looby M; Pönicke K; Zipprich B; Weiss M
    J Clin Pharmacol; 1996 Oct; 36(10):897-902. PubMed ID: 8930776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.